205 related articles for article (PubMed ID: 17701719)
1. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark.
Bracher L; Valerius NH; Rosenfeldt V; Herlin T; Fisker N; Nielsen H; Obel N
Scand J Infect Dis; 2007; 39(9):799-804. PubMed ID: 17701719
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).
Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J
Clin Infect Dis; 2010 Jul; 51(2):214-24. PubMed ID: 20536367
[TBL] [Abstract][Full Text] [Related]
4. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
Viani RM; Araneta MR; Deville JG; Spector SA
Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
6. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
7. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
10. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Tonwe-Gold B; Ekouevi DK; Viho I; Amani-Bosse C; Toure S; Coffie PA; Rouet F; Becquet R; Leroy V; El-Sadr WM; Abrams EJ; Dabis F
PLoS Med; 2007 Aug; 4(8):e257. PubMed ID: 17713983
[TBL] [Abstract][Full Text] [Related]
12. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
[TBL] [Abstract][Full Text] [Related]
14. Extensive implementation of highly active antiretroviral therapy shows great effect on survival and surrogate markers in vertically HIV-infected children.
Resino S; Bellon JM; Resino R; Navarro ML; Tomás Ramos J; de José MI; Mellado MJ; Muñoz-Fernández MA
Clin Infect Dis; 2004 Jun; 38(11):1605-12. PubMed ID: 15156450
[TBL] [Abstract][Full Text] [Related]
15. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
Kline MW; Rugina S; Ilie M; Matusa RF; Schweitzer AM; Calles NR; Schwarzwald HL
Pediatrics; 2007 May; 119(5):e1116-20. PubMed ID: 17420261
[TBL] [Abstract][Full Text] [Related]
17. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004.
Lohse N; Obel N; Kronborg G; Jørgensen LB; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
Antivir Ther; 2006; 11(5):591-600. PubMed ID: 16964827
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
19. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.
Grosch-Woerner I; Puch K; Maier RF; Niehues T; Notheis G; Patel D; Casteleyn S; Feiterna-Sperling C; Groeger S; Zaknun D;
HIV Med; 2008 Jan; 9(1):6-13. PubMed ID: 18199167
[TBL] [Abstract][Full Text] [Related]
20. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]